164 related articles for article (PubMed ID: 33908275)
21. Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.
Cole AL; Jazowski SA; Dusetzina SB
Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1529-1533. PubMed ID: 31507005
[TBL] [Abstract][Full Text] [Related]
22. Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.
McGarvey N; Gitlin M; Fadli E; Chung KC
J Med Econ; 2023; 26(1):1318-1329. PubMed ID: 37907436
[TBL] [Abstract][Full Text] [Related]
23. Federal Parity and Spending for Mental Illness.
Kennedy-Hendricks A; Epstein AJ; Stuart EA; Haffajee RL; McGinty EE; Busch AB; Huskamp HA; Barry CL
Pediatrics; 2018 Aug; 142(2):. PubMed ID: 30037977
[TBL] [Abstract][Full Text] [Related]
24. Parity and out-of-pocket spending for children with high mental health or substance abuse expenditures.
Barry CL; Chien AT; Normand SL; Busch AB; Azzone V; Goldman HH; Huskamp HA
Pediatrics; 2013 Mar; 131(3):e903-11. PubMed ID: 23420919
[TBL] [Abstract][Full Text] [Related]
25. Trend in Tyrosine Kinase Inhibitor Utilization, Price, and Out-of-Pocket Costs in Patients With Chronic Myelogenous Leukemia.
Talon B; Calip GS; Lee TA; Sharp LK; Patel P; Touchette DR
JCO Oncol Pract; 2021 Nov; 17(11):e1811-e1820. PubMed ID: 33961496
[TBL] [Abstract][Full Text] [Related]
26. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
Shen C; Zhao B; Liu L; Shih YT
Cancer; 2018 Jan; 124(2):364-373. PubMed ID: 28976559
[TBL] [Abstract][Full Text] [Related]
27. Association between prescription cost sharing and adherence to initial combination antiretroviral therapy in commercially insured antiretroviral-naïve patients with HIV.
Johnston SS; Juday T; Seekins D; Espindle D; Chu BC
J Manag Care Pharm; 2012 Mar; 18(2):129-45. PubMed ID: 22380472
[TBL] [Abstract][Full Text] [Related]
28. Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans.
Leopold C; Wagner AK; Zhang F; Lu CY; Earle CC; Nekhlyudov L; Ross-Degnan D; Wharam JF
Breast Cancer Res Treat; 2018 Sep; 171(2):449-459. PubMed ID: 29855813
[TBL] [Abstract][Full Text] [Related]
29. Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients.
Rivera DR; Enewold L; Barrett MJ; Banegas MP; Filipski KK; Freedman AN; Lam CK; Mariotto A
J Manag Care Spec Pharm; 2020 Dec; 26(12):1494-1504. PubMed ID: 33251998
[No Abstract] [Full Text] [Related]
30. State Mandate Laws for Autism Coverage and High-Deductible Health Plans.
Barry CL; Kennedy-Hendricks A; Mandell D; Epstein AJ; Candon M; Eisenberg M
Pediatrics; 2019 Jun; 143(6):. PubMed ID: 31092588
[TBL] [Abstract][Full Text] [Related]
31. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN; Keating NL; Dusetzina SB
J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
[TBL] [Abstract][Full Text] [Related]
32. The Effect of Reduced Drug Copayments on Adherence to Oral Diabetes Medications Among Childless Adults in Wisconsin Medicaid.
Kim NH; Look KA
J Manag Care Spec Pharm; 2019 Dec; 25(12):1432-1441. PubMed ID: 31778619
[TBL] [Abstract][Full Text] [Related]
33. Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents.
Doshi JA; Li P; Huo H; Pettit AR; Armstrong KA
J Clin Oncol; 2018 Feb; 36(5):476-482. PubMed ID: 29261440
[TBL] [Abstract][Full Text] [Related]
34. Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer.
Narang AK; Nicholas LH
JAMA Oncol; 2017 Jun; 3(6):757-765. PubMed ID: 27893028
[TBL] [Abstract][Full Text] [Related]
35. Impact of Patient Reimbursement Timing and Patient Out-of-Pocket Expenses on Medication Adherence in Patients Covered by Private Drug Insurance Plans.
Després F; Forget A; Kettani FZ; Blais L
J Manag Care Spec Pharm; 2016 May; 22(5):539-47. PubMed ID: 27123915
[TBL] [Abstract][Full Text] [Related]
36. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.
Latremouille-Viau D; Guerin A; Nitulescu R; Gagnon PS; Joseph GJ; Chen L
J Med Econ; 2017 Jan; 20(1):63-71. PubMed ID: 27603674
[TBL] [Abstract][Full Text] [Related]
38. Impact of initiating oral anticancer agents for leukemia on adherence to medications for multiple chronic conditions.
Gatwood J; Dashputre A; Rajpurohit A; Gatwood K; Mackler E; Wallace L; Farris K; Rizvi-Toner A; Farley J
J Oncol Pharm Pract; 2024 Mar; 30(2):342-353. PubMed ID: 37113049
[TBL] [Abstract][Full Text] [Related]
39. The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?
Kircher SM; Meeker CR; Nimeiri H; Geynisman DM; Zafar SY; Shankaran V; de Souza J; Wong YN
Value Health; 2016 Jan; 19(1):88-98. PubMed ID: 26797241
[TBL] [Abstract][Full Text] [Related]
40. Effect of Out-of-Pocket Costs on Subsequent Mammography Screening.
Tran L; Chetlen AL; Leslie DL; Segel JE
J Am Coll Radiol; 2022 Jan; 19(1 Pt A):24-34. PubMed ID: 34748732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
